Abstract-Angiotensin II (Ang II) has important actions on the heart via type 1 (AT 1 ) and type 2 (AT 2 ) receptors. The link between AT 1 receptor activation and the hypertrophy of cardiomyocytes is accepted, whereas the contribution of the AT 2 receptor, which reportedly antagonizes the AT 1 receptor, is contentious. This ambiguity is primarily based on in vivo approaches, in which the direct effect of the AT 2 receptor and its modulation of the AT 1 receptor (at the level of the cardiomyocyte) are difficult to establish. In this study, we used adenoviruses encoding AT 1 and AT 2 to coexpress these receptors in isolated cardiomyocytes, allowing a direct examination of the consequence of varying AT 1 /AT 2 stoichiometry on cardiomyocyte hypertrophy. Key Words: angiotensin II Ⅲ hypertrophy Ⅲ myocytes Ⅲ rats Ⅲ receptors L eft ventricular hypertrophy (LVH) is a major independent risk factor for premature death. 1 Extensive experimental and clinical evidence supports a role for the vasoactive hormone angiotensin II (Ang II) in the development of hypertension and the associated cardiomyocyte enlargement, which is a hallmark of LVH. Ang II binds with high affinity to type 1 (AT 1 ) and type 2 (AT 2 ) Ang II receptors, which are 7-transmembrane spanning, G-protein-coupled receptors. 2 AT 1 receptors are well characterized and mediate the established actions of Ang II, including vasoconstriction, aldosterone and vasopressin release, renal sodium reabsorption, increased collagen deposition, cellular proliferation, and, importantly, cardiomyocyte hypertrophy. The role of the AT 2 receptor is less clear, but current theories favor a role in opposing the actions of the AT 1 receptor. 3-7 AT 2 receptors are highly expressed in the fetus; however, after birth, the AT 2 receptor expression decreases to low levels. 2 In normal, adult human and rat hearts, AT 1 and AT 2 receptors are expressed, 8 -10 and they have been shown to be upregulated during cardiovascular pathologies. 8, 9 The specific signaling pathways activated via the AT 2 receptor remain poorly resolved, although AT 2 receptors reportedly inhibit AT 1 receptor signaling pathways, such as extracellular signalregulated kinase 1/2 (ERK1/2) mitogen-activated protein kinases (MAPKs), by activating specific tyrosine or serine/ threonine phosphatases. 6, 11, 12 More recent evidence suggests functional heterodimerization between the AT 1 and AT 2
L eft ventricular hypertrophy (LVH) is a major independent risk factor for premature death. 1 Extensive experimental and clinical evidence supports a role for the vasoactive hormone angiotensin II (Ang II) in the development of hypertension and the associated cardiomyocyte enlargement, which is a hallmark of LVH. Ang II binds with high affinity to type 1 (AT 1 ) and type 2 (AT 2 ) Ang II receptors, which are 7-transmembrane spanning, G-protein-coupled receptors. 2 AT 1 receptors are well characterized and mediate the established actions of Ang II, including vasoconstriction, aldosterone and vasopressin release, renal sodium reabsorption, increased collagen deposition, cellular proliferation, and, importantly, cardiomyocyte hypertrophy. The role of the AT 2 receptor is less clear, but current theories favor a role in opposing the actions of the AT 1 receptor. [3] [4] [5] [6] [7] AT 2 receptors are highly expressed in the fetus; however, after birth, the AT 2 receptor expression decreases to low levels. 2 In normal, adult human and rat hearts, AT 1 and AT 2 receptors are expressed, 8 -10 and they have been shown to be upregulated during cardiovascular pathologies. 8, 9 The specific signaling pathways activated via the AT 2 receptor remain poorly resolved, although AT 2 receptors reportedly inhibit AT 1 receptor signaling pathways, such as extracellular signalregulated kinase 1/2 (ERK1/2) mitogen-activated protein kinases (MAPKs), by activating specific tyrosine or serine/ threonine phosphatases. 6, 11, 12 More recent evidence suggests functional heterodimerization between the AT 1 and AT 2 receptors, in which the AT 2 receptor antagonizes the actions of the AT 1 receptor. 13 The widely accepted notion that the AT 2 receptor simply counteracts the vasoactive roles of the AT 1 receptor is being increasingly challenged. 14, 15 For example, AT 2 receptors have been shown to decrease 7, 16 or not affect blood pressure and 17 to inhibit, 18 -20 increase, 21, 22 and not affect 23 collagen deposition. They have been shown to be involved in fetal development 24 and cause cellular differentiation. 25, 26 AT 2 receptors have been reported to inhibit 7, 18, 27 or stimulate 28 vascular growth and angiogenesis, inhibit 20, 26, 27, 29 and not affect 23 cellular proliferation, and cause 6, 30, 31 or not affect 32 apoptosis. Most important, AT 2 receptors have been shown to lead to either stimulation of, 21, 22, 33 inhibition of, 34 or not affect 18, 19, 32 cardiac hypertrophy. At least part of this inconsistency relates to the experimental approaches used. For example, most of the studies examining the role of the AT 2 receptor in cardiac hypertrophy have been conducted in vivo using wild-type and AT 2 receptor transgenic or knockout animals. Although powerful, such studies can be problematic because of strain differences and complicated by other cellular, circulating, and paracrine factors. Studies aimed at investigating the direct effects of Ang II on cultured cardiomyocytes have also yielded ambiguous results, primarily because of low and variable expression of AT 1 and AT 2 receptors and inconsistent hypertrophy in such models. We have recently shown that Ang II-mediated hypertrophy can be reproducibly demonstrated in cultured cardiomyocytes infected with recombinant AT 1 receptors. 35 To directly investigate the effect of activating the AT 2 receptor on cardiomyocyte hypertrophy, we developed an adenovirus expressing the AT 2 receptor, which has allowed us to tightly control the ratio of AT 1 :AT 2 receptor expression in these cells. We report that the AT 2 receptor causes constitutive cardiomyocyte hypertrophy, which is independent of Ang II and in contrast to some prevailing theories, and the AT 2 receptor does not antagonize the hypertrophic actions and signals of the AT 1 receptor.
Materials and Methods

Generation of AdNHA-AT1 and AdNHA-AT2
A plasmid containing the rat AT 2 receptor gene (obtained from Dr T.J. Murphy, Emory University School of Medicine) was subcloned into the mammalian expression vector pRc/CMV at HindIII/XbaI (pRc/CMV-AT2). A hemagglutinin antigen (HA) epitope tag was introduced at the N terminus (pRc/CMV-NHA-AT2) using the ExSite Mutagenesis kit (Stratagene). The recombinant AT 2 receptor adenovirus (AdNHA-AT2) was produced using the method described by He et al. 36 The coding region of the NHA-AT2 was subcloned into the pAdTrack-CMV shuttle vector, obtained from Dr B. Vogelstein 36 (Johns Hopkins Oncology Center, Baltimore, Md), using HindIII and XbaI linkers to yield pAdTrackNHA-AT2. pAdTrackNHA-AT2 underwent bacterial homologous recombination with pAdEasy-1, generating recombinant adenoviruses (AdNHA-AT2). AdNHA-AT2 and AdNHA-AT1 viral stock titers used were 0.37ϫ10 9 plaque forming units (PFU)/L and 0.22ϫ10 9 PFU/L, respectively (the AT 1 receptor adenovirus [AdNHA-AT1] has been reported previously 35 ).
Cell Culture
Cardiomyocytes isolated from 1-day-old Sprague-Dawley rat ventricles were plated at high density in 12-well plates at 0.475ϫ10 6 ; for phalloidin staining) as described previously. 37 Cardiomyocytes plated at high density were grown in modified Eagle's medium with 10% bovine calf serum for 24 hours, then in defined, serum-free media with KCl (50 mmol/L) to arrest spontaneous beating. 37 Animals, supplied by the Precinct Animal Centre (Alfred Medical Research and Education Precinct, Prahran, Melbourne, Australia), were handled in accordance with the Australian code of practice for the care and use of animals for scientific purposes.
Adenoviral Infection of Cardiomyocytes
After 24-hour incubation in defined serum-free media, cardiomyocytes were infected with 3 levels of AdNHA-AT1, termed L_ (low; multiplicity of infection (MOI)ϭ8; 4ϫ10 6 
Characterization of AdNHA-AT2
The AT 1 and AT 2 receptors were detected, quantified, and characterized in AdNHA-AT1-infected and AdNHA-AT2-infected cardiomyocytes 48 hours after infection via equilibrium competition binding assays. 35 
Cardiomyocyte Hypertrophy
Forty-eight hours after adenoviral infection, cardiomyocytes were stimulated with Ang
Blockers were administered 30 minutes before Ang II stimulation, when in combination. Seventy-two hours after stimulation, cardiomyocytes were harvested, and hypertrophy, defined as increased protein:DNA ratio, was determined as described previously. 35 
Phalloidin Staining
Low-density cardiomyocytes were stained with tetramethylrhodamine B isothiocyanate (TRITC)-labeled phalloidin (Sigma) as described previously. 35, 37 This allows a visualization of sarcomeric reorganization, a feature of cardiomyocyte hypertrophy, in these cells.
ERK1/2 Activity
ERK1/2 activation and expression were examined using Western blots probed with monoclonal phospho-p44/42 antibody (Cell Signaling Technology) and anti-ERK1 antibody (Santa Cruz Biotechnology) as described previously. 35, 37 
Statistical Analysis
All data are presented as meanϮSEM. For comparisons between 2 groups, a Student t test was used. For all multigroup comparisons, data were analyzed using a 1-way ANOVA followed by a Tukey's post hoc test. Significance was accepted at PϽ0.05. Grouped data are from 4 separate experiments, each of which involved triplicate wells assayed in duplicate.
Results
Characterization of AdNHA-AT2
Binding of [
125 I]-Ang II to AT 1 receptors expressed on cardiomyocytes using the adenovirus was displaced with high affinity by Ang II and the AT 1 receptor specific ligand candesartan but not the AT 2 receptor specific ligands PD123319 and CGP42112A ( Figure 1A ). [
125 I]-Ang II binding to AT 2 receptors expressed on cardiomyocytes was displaced with Ang II, PD123319, and CGP42112A but not candesartan, confirming AT 2 receptor adenoviral expression ( Figure 1B) .
AT 2 receptor expression was titrated with different amounts of AdNHA-AT2, designated low (L_), medium (M_), and high (H_; Figure 1C ). Infection with M_AdNHA-AT2 resulted in Ϸ400-fmol receptor/mg protein ( Figure 1C ) similar to that of M_AdNHA-AT1-infected cells, which produced Ϸ500-fmol receptor/mg protein. 35 Figure 1D shows expression of the AT 1 receptor compared with the titrated AT 2 receptor in cardiomyocytes. Receptors were immunoprecipitated and Western blotted for the N-terminal HA epitope. AdNHA-AT2-infected cardiomyocytes showed increased AT 2 receptor expression with increased viral titer (Figure 1D) ; the level of receptor protein generated by M_AdNHA-AT2 was similar to that produced by M_AdNHA-AT1, confirming the radioligand binding data.
Characterization of Uninfected Cardiomyocytes
In uninfected neonatal rat cardiomyocytes, radioligand binding of [
125 I]-Ang II showed very low to undetectable levels of endogenous AT 1 and AT 2 receptors (data not shown). These myocytes failed to hypertrophy after Ang II stimulation (Figure 2 ), as measured by protein content normalized to cellular DNA. We previously demonstrated that these cells are capable of Ϸ30% hypertrophy by activation of endogenous ␣ 1 -adrenergic receptors and that the lack of Ang II-induced hypertrophy is attributable to low AT 1 receptor expression in these highly purified cultures. 35 Low levels of endogenous Ang II receptors in neonatal cardiomyocytes and the absence of Ang II-mediated hypertrophy makes this model ideal for introducing AT 1 and AT 2 receptors and examining their interactions in a controlled manner.
Hypertrophic Effects of AT 1 Receptors
As observed previously, 35 increasing the expression of AT 1 receptors on cardiomyocytes promoted robust Ang II-stimulated hypertrophy ( Figure 3A) . However, increasing the expression of the AT 1 receptor on cardiomyocytes does not increase basal (in the absence of Ang II) cardiomyocyte hypertrophy. The Ang II-stimulated hypertrophy observed in M_AdNHA-AT1-infected cardiomyocytes (125Ϯ3%; where uninfected, unstimulated control is 100%) was reversed by candesartan treatment but unaffected by the AT 2 receptor ligands ( Figure 3B ). The phenotypic changes that occur during Ang II-induced hypertrophy of M_AdNHA-AT1-infected cardiomyocytes can be clearly seen by examination of GFP fluorescence (resulting from virus infection) and phalloidin staining ( Figure 3C ). 
Hypertrophic Effects of AT 2 Receptors
In contrast to the AT 1 receptor, increasing the expression of the AT 2 receptor on cardiomyocytes led to a concomitant increase in basal hypertrophy ( Figure 4A ), which was unaffected by treatment with any of the Ang II receptor ligands (Ang II, PD123319, CGP42112A, or candesartan; Figure  4B ). The MAPK inhibitor PD98059 was unable to inhibit this constitutive growth ( Figure 4B ), although it abrogates Ang II-mediated growth via the AT 1 receptor. 35 H_AdNHA-AT2-infected cardiomyocytes show a hypertrophic phenotype, in the absence of Ang II stimulation, when examining GFP labeling and phalloidin staining ( Figure 4C ).
To confirm that the AT 2 constitutive growth did not result from a nonspecific adenoviral effect, we infected cells with a control backbone adenovirus (AdGO; MOIϭ17; 8ϫ10 6 PFU, which matched the level of GFP fluorescence of H_AdNHA-AT2) and observed no change in basal hypertrophy compared with the uninfected control (data not shown).
Hypertrophic Effects of Coexpressing the AT 1 and AT 2 Receptors
We next investigated whether coexpression of the AT 2 receptor could modify the hypertrophic response of AT 1 receptor activation. As shown in Figure 5 , increasing AT 2 receptor expression did not inhibit Ang II-mediated hypertrophy through the AT 1 receptor. AT 2 receptor-mediated enhanced basal hypertrophy was maintained and was additive to that of the AT 1 receptor, indicating that these receptors are impinging on separate pathways. The AT 1 receptor component was inhibited by candesartan. Treatment with the AT 2 receptor antagonist PD123319 did not reverse the Ang II hypertrophic response, and stimulation of the AT 2 receptors with the agonist CGP42112A before Ang II stimulation of the AT 1 receptors also did not inhibit hypertrophy ( Figure 5B ). 
Effect of the AT 1 and AT 2 Receptors on MAPK Activity
Previous studies have indicated that the AT 2 receptor may antagonize the capacity of AT 1 receptors to activate ERK1/2 MAPK. 6 AT 1 receptor-mediated ERK1/2 activation after Ang II stimulation was unaffected by coexpression of equal or greater amounts of AT 2 receptor (Figure 6 ).
Discussion
The contribution (either positive or negative) of the AT 2 receptor to cardiac hypertrophy is equivocal. 5 ,18,21,22,33,34,41 In the present study, we used cultured neonatal cardiomyocytes (which express low to undetectable levels of Ang II receptors) and recombinant adenoviruses, encoding the AT 1 and AT 2 receptors, to examine the involvement of the AT 2 receptor in cardiomyocyte hypertrophy. The main advantage of our approach is that the degree and stoichiometry of AT 1 and AT 2 receptor expression can be varied, and it is possible to directly examine the hypertrophy of cardiomyocytes in isolation. Thus, we were able to express different ratios and amounts of AT 1 and AT 2 receptors and then determine the effect on cardiomyocyte hypertrophy in response to Ang II stimulation and in the presence and absence of AT 1 and AT 2 selective ligands. We show that increasing the AT 2 receptor expression in cardiomyocytes leads to a ligand-independent increase in basal hypertrophy. Importantly, we also clearly document that Ang II-stimulated AT 1 receptor-mediated hypertrophy of isolated cardiomyocytes is unaffected by coexpression of the AT 2 receptor. Thus, in cardiomyocytes, the AT 2 receptor causes constitutive growth and does not oppose the actions of the AT 1 receptor.
A variety of elegant in vivo experimental approaches (including knockout, transgenic, and lentiviral AT 2 receptor expression) have attempted to delineate the role of the AT 2 receptor in cardiac hypertrophy. 5, 18, 21, 22, 33, 34, 41 In some studies, abolition 17 or cardiac-specific overexpression 5 of the AT 2 receptor failed to implicate this receptor in the modulation of LVH after Ang II infusion or aortic banding. 18, 19, 32 In contrast, in another AT 2 receptor knockout model (albeit in a different strain), 16 LVH was prevented after either Ang II infusion 21 or aortic constriction 22 compared with wild-type counterparts. This indicates the apparent importance of the AT 2 receptor in the development of LVH. Moreover, Yan et al 33 reported that ventricular-specific AT 2 receptor overexpression (using the myosin light chain promoter) leads to an increase in LVH in the absence of any external stimulus. Finally, delivery of AT 2 receptors to a subpopulation of cardiomyocytes and presumably other cells (because a cardiac-specific promoter was not used) using a bolus injection of an AT 2 receptor-expressing lentivirus 34 reportedly prevented the Ang II-dependent development of LVH that occurs in spontaneously hypertensive rats. 34 So despite much work, a coherent understanding of the role of the AT 2 receptor in cardiomyocyte hypertrophy has remained elusive, primarily because of the inherent complexity and compensatory mechanisms of in vivo/transgenic approaches or the lack of specificity afforded by a bolus viral injection in the heart. Moreover, most existing data on the AT 2 receptor (and its interpretation) hinge on the veracity of PD123319 antagonism. Although PD123319 is undoubtedly a selective inhibitor of Ang II binding to the AT 2 binding site, we would argue, based on our data and that of some others, 13, 31 that PD123319 cannot modulate all functions ascribed to this receptor. Most would agree that signaling from the AT 2 receptor has been difficult to unambiguously establish, and hence the term "antagonist" should be used with caution.
Our data, using adenoviral-directed AT 2 receptor expression, indicate a direct, prohypertrophic action for the AT 2 receptor on cardiomyocytes. Interestingly, none of the AT 2 receptor ligands examined (Ang II, PD123319, and CGP42112) could block or facilitate this effect, indicating that this receptor is constitutively active and that the presence of the AT 2 receptor alone is sufficient to drive this process. Although we cannot completely rule out that our results are a nuance of receptor overexpression, such an idea (ie, constitutive activity of the AT 2 receptor) has precedence. 31, [42] [43] [44] [45] For example, the AT 2 receptor displays ligand pharmacology consistent with it residing in a constant, active conformation. 43 This receptor induces apoptosis in the absence of Ang II stimulation, and the AT 2 receptor antagonist PD123319 does not modulate this effect. 31 In addition, Jin et al 44 showed that overexpression of the AT 2 receptor downregulates AT 1 receptor expression in vascular smooth muscle cells, with and without Ang II stimulation. In contrast to the AT 1 receptor, in which signal transduction pathways are well documented, the extent and type of intracellular signals that emanate from the AT 2 receptor have been difficult to define. 15, 46, 47 Thus, the molecular mechanisms and signals that generate constitutive activity in the AT 2 receptor remain elusive. Recently, it was suggested that in Chinese hamster ovary cells, homo-oligomerization of AT 2 receptors leads to constitutive cell signaling. 45 Given this emerging body of evidence, it would seem appropriate to consider reinterpreting some existing data based on consideration of a constitutive rather than ligand-activated AT 2 receptor.
Activation of ERK1/2 MAPKs has been strongly associated with hypertrophy of cardiomyocytes, 35 and there is evidence that the AT 2 receptor impinges on ERK1/2 activation. Although AT 2 receptors have been shown to induce MAPK activity in neuronal NG108 -15 cells, 48 most studies have pointed to an inhibitory action of the AT 2 receptor on ERK1/2 MAPK and growth, primarily via activation of the SH2 domain-containing tyrosine phosphatase (SHP-1), MAPK phosphatase-1, and serine/threonine phosphatase 2A pathways. 4, 6, 11, 12, 29, 49 Interestingly, Feng et al 49 could provide no evidence to support a constitutive activation of SHP-1 by the AT 2 receptor; instead, SHP-1 associated with the "inactive" AT 2 receptor and was released on Ang II stimulation. In cardiac fibroblasts, the AT 2 receptor inhibited protein tyrosine phosphatases but had no effect on MAPK ERK1/2 activity. 23 Our results show that AT 2 receptors alone do not alter ERK1/2 activity, and ERK inhibition did not alter AT 2 receptor constitutive growth. Thus, the mechanism of the constitutive cardiomyocyte growth remains to be determined, but it is clearly not via the MAPK pathway. Moreover, the AT 2 receptor did not inhibit AT 1 receptor-induced ERK1/2 activation, supporting our observation that AT 2 coexpression did not affect AT 1 -mediated hypertrophy. A potential prohypertrophic pathway of the AT 2 receptor has been suggested to involve this receptor binding to the promyelocytic zinc finger protein, which is then translocated to the nucleus and activates the p85␣ phosphatidylinositol 3-kinase gene leading to protein synthesis. 50 The major outcome of our study is that we can provide no evidence to support the widely stated view that the AT 2 receptor opposes the actions of the AT 1 receptor. AT 1 receptor-mediated cardiomyocyte hypertrophy was unaffected by coexpressing increasing levels of the AT 2 receptor. This was an unexpected finding because there is significant Figure 6 . AT 1 -mediated ERK1/2 activity is not altered by AT 2 receptor coexpression. ERK1/2 activation and expression were examined using Western blots probed with monoclonal phospho-p44/42 antibody and anti-ERK1 antibody. Ang II stimulation of cardiomyocytes expressing only AT 1 receptors showed a robust increase in MAPK activity. Coexpression of AT 2 receptors in cells not expressing or expressing adenovirus-directed AT 1 receptors had no effect on basal or Ang II-stimulated ERK1/2 activation.
literature suggesting that the AT 2 receptor opposes the growth actions of the AT 1 receptor, such as antiproliferation in vascular smooth muscle cells, 4 endothelial cells, 27 fibroblasts, 20, 29 and neuronal cells. 26 Indeed, a recent report 13 (that our data call into question) proposed that the AT 2 receptor can physically associate as a heterodimer with the AT 1 receptor and directly antagonize its actions. Although overexpression of the AT 2 receptor using lentivirus injection into the heart was also reported to inhibit/delay Ang II/AT 1 -dependent cardiac hypertrophy, 34, 41 this likely reflects nonmyocyte actions because expression of the AT 2 receptor was not driven by a cardiomyocyte-specific promoter. However, our results are in agreement with transgenic studies in which Ang II-mediated cardiac hypertrophy, via the AT 1 receptor, was unaffected by cardiomyocyte-specific overexpression of the AT 2 receptor. 19, 32 In summary, the ambiguous role of the AT 2 receptor in cardiomyocyte hypertrophy relates to conflicting interpretations of data from a variety of in vivo and in vitro studies. In this study, we examined the direct role of the AT 2 receptor in cardiomyocyte hypertrophy independently of in vivo complications. Using an AT 2 receptor expressing adenovirus to infect cardiomyocytes, we report that the AT 2 receptor causes constitutive cardiomyocyte hypertrophy via an ERK1/2 MAPK-independent pathway. Finally, our data refute the idea that the AT 2 receptor antagonizes the AT 1 receptor in the setting of cardiomyocyte hypertrophy or ERK1/2 MAPK activation.
Perspectives
The enigmatic nature of the AT 2 receptor has complicated a detailed appreciation of its contribution to cardiovascular regulation and, specifically, cardiac hypertrophy. Our data call into question the strongly held view that the AT 2 receptor opposes the actions of the AT 1 receptor, either by inhibiting AT 1 -mediated ERK1/2 activation or via direct antagonism mediated by heterodimerization between the 2 receptors. Instead, we favor a model in which both receptors independently impinge on cardiomyocyte growth. The next major challenge in this area will be to unambiguously establish the type and extent of intracellular signals emanating from the AT 2 receptor, particularly those that underlie its capacity to promote constitutive cardiomyocyte growth.
